CD8A and neoplasm: In part A, two anti-CD8 tracer protein doses (89ZED88082A + unlabeled, desferrioxamine (DFO)-conjugated one-armed antibody CED88004S) were evaluated: 4 mg (n = 3) or 10 mg (n = 6) with serial PET scans 0 (1 h), 2, 4 and 7 (±1) days after administration, followed by a biopsy of a tumor lesion.